Tesamorelin: The Only FDA-Approved Peptide for Visceral Fat in 35+

Have you ever heard of "dangerous" fat? Not the kind you see in the mirror. But the kind that accumulates deep inside, wrapping around your liver, intestines, pancreas. Visceral fat. It doesn't hurt. It doesn't interfere with buttoning your jeans. But it's exactly what triggers a cascade of metabolic problems: insulin resistance, inflammation, fatty liver disease, cardiovascular risks.

And here's the interesting part: there's a peptide that the FDA approved specifically to fight this internal enemy. Tesamorelin. Not for general weight loss. Not for subcutaneous fat. But specifically - for visceral adipose tissue. Let's understand how this works.

What is Tesamorelin and what's its history?

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). Simply put: your hypothalamus produces a signaling molecule GHRH that tells the pituitary "produce more growth hormone." Tesamorelin mimics this natural signal [2].

The molecule consists of 44 amino acids - identical to natural GHRH(1-44). But with one trick: trans-3-hexenoic acid is added to the beginning of the molecule. This modification protects the peptide from rapid degradation by enzymes in the blood [2].

The FDA approval history began in November 2010. Then the U.S. Food and Drug Administration approved tesamorelin under the trade name Egrifta. Indication: reduction of excess abdominal fat in HIV-infected patients with lipodystrophy [22][26].

Why is this important? Because FDA approval means solid clinical foundation. Thousands of patients in controlled studies. Documented efficacy and safety. This isn't a "research peptide" from a gray zone - it's a full-fledged pharmaceutical [2].

In March 2025, the FDA approved an updated version - Egrifta WR (tesamorelin F8) with an improved formula [23]. So this peptide continues to evolve.

How Tesamorelin works: amplifying the natural GH wave

This is where the real science begins. And it's fascinating.

Tesamorelin doesn't "give" your body growth hormone from outside. It "asks" your body to produce more of its own. This difference is fundamental for safety and efficacy [12].

When you make a subcutaneous injection, the tesamorelin molecule travels through the bloodstream to the anterior pituitary. There it binds to specific GHRH receptors on somatotroph cells [2][5].

What happens next? Receptor activation triggers a cascade of intracellular events: adenylate cyclase stimulation → cAMP elevation → protein kinase A activation → transcriptional regulator phosphorylation [11]. Result: growth hormone (GH) synthesis and secretion.

Most importantly: tesamorelin preserves the pulsatile nature of GH secretion. Growth hormone is released in waves, mainly during sleep - not as a constantly elevated level. Stanley et al. study showed: tesamorelin increases GH pulse amplitude without changing their frequency [4].

Why is this critical? Pulsatile secretion has a different effect on tissues than constantly elevated GH levels. Natural rhythm - that's what distinguishes tesamorelin from direct exogenous growth hormone administration [2].

Plus negative feedback is preserved. When GH rises, somatostatin increases, inhibiting further secretion. This self-regulation remains intact. The risk of excess GH/IGF-1 is minimized [17].

Key LIPO-2009 study: what the numbers showed

Now to specifics. Falutz and colleagues conducted a large-scale study whose results became the basis for FDA approval.

Study design:

• 412 HIV-infected patients with abdominal fat accumulation
• 86% men
• 2:1 randomization (tesamorelin 2 mg vs placebo)
• Daily subcutaneous injections for 26 weeks [1][3]

Primary endpoint: change in visceral adipose tissue (VAT).

Results were striking:

Note: -27.8 cm² vs -5.1 cm². The difference is statistically significant (p < 0.001) [3].

In the extended 12-month follow-up, patients who continued taking tesamorelin achieved approximately 18% VAT reduction [14]. Meanwhile, subcutaneous fat (SAT) remained virtually unchanged - the effect was selective for visceral tissue [9].

IGF-1 also increased. In the Falutz et al. study: +79 ng/ml at 1 mg dose, +103 ng/ml at 2 mg dose (vs +22 ng/ml in placebo) [3]. This confirms the mechanism of action through the GH-IGF-1 axis.

Who is Tesamorelin indicated for: ideal candidate profile

The official FDA indication is HIV-associated lipodystrophy. But tesamorelin's mechanism of action made it interesting for a broader audience in the context of metabolic health.

Who could benefit most?

Criteria from clinical studies:

• Men: waist circumference ≥95 cm, WHR ≥0.94
• Women: waist circumference ≥94 cm, WHR ≥0.88 [3]

These parameters are markers of visceral fat accumulation. Not just "excess weight," but specifically central obesity with metabolic risks.

Ideal profile for off-label use (35+):

• Age 35-60 years (when natural GH secretion declines)
• Metabolic syndrome or its components
• Insulin resistance
• Fatty liver disease (NAFLD) - tesamorelin showed 40% relative liver fat reduction [16]
• Plateau after successful GLP-1 agonist course

Important to understand: tesamorelin is not intended for general weight loss. The FDA clearly states: the drug is not indicated for weight loss and has a weight-neutral effect [28]. It specifically attacks visceral fat without affecting subcutaneous fat.

Application protocol: 2 mg/day for 26 weeks

What does a standard tesamorelin course look like?

Timing: morning, on empty stomach. This aligns with natural GH secretion peaks and minimizes food interactions [5].

Location: subcutaneous in abdomen. Tesamorelin is an amidated GHRH(1-44) peptide with stabilization against degradation. Half-life after subcutaneous administration is 26-38 minutes [4].

Monitoring:

• IGF-1: weeks 4, 12, 24
• Fasting glucose and HbA1c: every 8 weeks
• Abdominal CT or MRI (VAT): before/after course

Page Tesamorelin buy in Ukraine — the only FDA-approved peptide for visceral fat. Original product with DOZA specialist support at every stage of the program.

Tesamorelin vs Ipamorelin+CJC-1295: what to choose?

This question comes up often. Both options stimulate growth hormone secretion. But mechanisms and action profiles are different.

Key difference:

Tesamorelin - GHRH analog. Binds to GHRH receptors in the pituitary. Acts "from above" on the GH axis [12].

Ipamorelin - ghrelin mimetic (GHS-R agonist). Binds to ghrelin receptors - a completely different signaling pathway [7][10].

CJC-1295 — also a GHRH analogue, but with a different modification (DAC — Drug Affinity Complex), which extends the half-life [6].

Important warning regarding Ipamorelin and CJC-1295: FDA has issued warning letters to companies selling these peptides. They are not approved for any human use and cannot be legally compounded [39][41].

If your goal is targeted reduction of visceral fat with proven efficacy and legal status, tesamorelin has clear advantages. For general anti-aging and recovery, the combination Ipamorelin+CJC-1295 can be considered, but with understanding of regulatory risks.

Side effects and contraindications: what to expect?

Tesamorelin has undergone thorough safety evaluation in clinical studies. Overall, the drug is well tolerated [9].

Most common side effects:

• Injection site reactions (pain, redness, itching) - most common effect
• Edema (peripheral) - related to fluid retention due to elevated GH
• Arthralgia (joint pain)
• Transient elevation of fasting glucose and HbA1c [3][9]

Regarding glucose impact: this is an expected effect of elevated GH. Growth hormone has counter-insulin action. In most cases, changes are reversible after therapy discontinuation.

Contraindications:

• Active malignancies (GH may stimulate proliferation)
• Pituitary insufficiency or pituitary tumors
• Pregnancy and lactation
• Known allergic reactions to tesamorelin or mannitol (excipient)
• Uncontrolled type 2 diabetes [28]

Important: long-term cardiovascular safety of tesamorelin has not yet been studied in dedicated trials [28]. Therefore, courses are limited to 26-52 weeks with mandatory breaks.

Synergy with Mounjaro: how to combine for maximum results?

This is where weight management strategy reaches a new level.

Mounjaro (Mounjaro) — dual GLP-1/GIP agonist — works excellently for appetite reduction and overall weight loss. The SURMOUNT-1 study showed up to -22.5% weight loss at maximum dose [1].

But GLP-1 agonists work systemically. They reduce both subcutaneous and visceral fat. Tesamorelin specifically targets VAT.

When to add Tesamorelin to a Mounjaro program?

• After stabilization on target Mounjaro dose (usually weeks 12+)
• When reaching a plateau in waist circumference reduction
• When VAT remains elevated despite weight loss

Such a combination allows attacking visceral adiposity from two fronts. More details about weight correction programs — on the DOZA weight loss programs page.

Where to order Tesamorelin in Ukraine?

Tesamorelin buy in Ukraine — the only FDA-approved peptide for visceral fat. Selectively works on VAT with proven -18% over 26 weeks (LIPO-2009) [14].

For comprehensive strategy after GLP-1 plateau: Mounjaro buy in Ukraine + Tesamorelin after week 12 of Mounjaro (when dose has stabilized).

We also recommend reviewing:

• How to remove belly and sides: 5 scientific methods
• Peptides for weight loss: comparison of 10 options 2026

Where to buy

DOZA supplies the products mentioned in this article with an official cold chain and 24/7 specialist support:

• Buy Ipamorelin in Ukraine — selective GHRP peptide to stimulate natural growth hormone.
• Buy CJC-1295 in Ukraine — long-acting GHRH analog that boosts Ipamorelin's effect.

FAQ: answers to the most common questions